Cardiac hypertrophy is a common pathological change frequently accompanied by chronic hypertension and myocardial infarction. Nevertheless, the pathophysiological mechanisms of cardiac hypertrophy have never been elucidated. Recent studies indicated that miR-103 expression was significantly decreased in heart failure patients.
| INTRODUCTION
Cardiac hypertrophy is an adaptive response to the increased blood pressure and afterload, and is also a common pathophysiological process in many cardiovascular diseases such as hypertension, myocardial infarction, valvular heart disease, cardiomyopathy and so on. 1, 2 Despite, the hypertrophic response is a compensatory mechanism that augments cardiac output, sustained hypertrophy can lead to dilated cardiomyopathy, heart failure and sudden cardiac death. In the western country, approximately half a million individuals are diagnosed with heart failure each year, with a mortality rate approaching 50%. There have been major advances in the identification of genes and signalling pathways involved in this disease process, but the overall complexity of hypertrophic remodelling suggests that additional regulatory mechanisms remain to be identified. Therefore, identifying new molecular mechanisms mediating cardiac hypertrophy and providing new targets for clinical treatment need to be addressed.
MicroRNAs (miRNAs), as the endogenous, non-coding and singlestranded RNAs of approximate 22 nucleotides, can directly regulate more than 30% of the genes in a cell, 3 which are major regulators of cell differentiation, growth, proliferation and apoptosis. [4] [5] [6] Similarly, many miRNAs are now also known to participate in regulating cardiac hypertrophy, such as miR-133, miR-195, miR-1 [7] [8] [9] and so on.
MiR-103 is a member of the miR-103/107 family located on human chromosome 5. 10 It is widely distributed in 13 kinds of human normal tissues (liver, placenta, brain, heart, stomach, lung, bladder, prostate, colon, thymus, ovaries, fat and uterus), and five kinds of carcinoma. 11 Recent studies have also shown that miR-103 expression was significantly lowered in heart failure patients than healthy volunteers. 12 However, the role of miR-103 in protecting against cardiac hypertrophy has never been elucidated.
We used targetscan software to predict the downstream of miR-103, and found that TRPV3 was the underlying target of miR-103.
TRPV3, a non-selective cation channel, belongs to the Ca 2+ -permeant TRP channel family, and which functions in the formation of the skin barrier, hair growth, wound healing and temperature sensation. [13] [14] [15] [16] TRPV3 can be activated by warm temperatures above 33°C and natural herbs such as carvacrol and inhibited by ruthenium red. In recent years, many studies have expanded the functions of TRP channels, and confirmed that they participated in the regulation of various diseases such as anxiety, asthma, obesity and metabolic disorders. 17 In particular, TRP channels are also involved in the regulation of cardiovascular disease. TRPV4 is an important regulator of intracellular Ca 2+ concentration in cardiac fibroblasts. 18 It has also been reported that TRPV1 was up-regulated in pathological myocardial hypertrophy. 19 According to our previous study, TRPV3 activation exacerbated cardiac fibrosis by promoting cardiac fibroblast proliferation through TGF-β 1 /CDK2/cyclin E pathway in the pressureoverloaded rat hearts. 20 Interestingly, the overall sequence of TRPV3 has 40% homology to TRPV1. 21 Therefore, we speculate whether TRPV3 is also involved in the occurrence of cardiac hypertrophy.
Autophagy is a conserved, tightly regulated intracellular catabolic process, in which mammalian cells degrade and recycle the damaged and dysfunctional macromolecules and organelles. Recent findings suggest that autophagy exploits a variety of physiological functions to maintain the balance of cardiac homeostasis. 22 For example, a certain extent of autophagy is crucial for proper heart function, whereas exaggerated autophagic activity may foster many cardiovascular diseases such as cardiac hypertrophy, cardiac ischaemia/reperfusion injury, heart failure and so on. 23 were induced to myocardial hypertrophy via abdominal aorta coarctation. All animal experiments were conducted in accordance with the protocols approved by the Experimental Animal Ethics Committee of Harbin Medical University. In short, the male Wistar rats were anaesthetized with sodium pentobarbital (40 mg/kg, i.p.), and the abdomen was opened on aseptic conditions. Under sterile conditions, the abdominal aorta was separated for 1 cm segment above the double renal artery, and a diameter of 0.7 mm silver wire was placed on the surface of the abdominal aorta. Then, the abdominal aorta and wire were tightly tied together by surgical silks, and a constriction of the abdominal aorta was provided. The wire was withdrawn from the ligature, so that remaining orifice of the abdominal aorta could close to that of the wire. The rats were divided into three groups randomly: control group, model group and sham group.
Sham group underwent laparotomy only, not for abdominal aortic constriction. The ratio of heart weight (HW) to bodyweight (BW) was measured 4 weeks after aortic constriction. 
| Haematoxylin-Eosin staining
The left ventricle of male Wistar rat was placed in 4% paraformaldehyde solution at 4°C overnight, then, added 30% sucrose solution.
The left ventricle tissue was sunk to the bottom of 30% sucrose solution, embedded in OCT-freeze medium and frozen at −20°C.
Sections of several micron thickness were knifed and transferred to 3-aminopropyl triethoxysilane-coated slides. These sections were stained with haematoxylin-eosin (HE), and the histopathological abnormalities were investigated under the light microscope. The photographs were captured with an Olympus BX60 microscope (Olympus Optical Co. Ltd., Tokyo, Japan).
| Cell culture and microRNA transfection
Myocardial cells were isolated and cultured as described. 27 In brief, the hearts removed from neonatal rats (1to3-day-old) were finely 
| TRPV3 silencing
Cells were plated in 6-well plates and cultured for 48 hours. Cardiomyocytes were transfected with the X-tremeGENE small interfering RNA (siRNA) transfection reagent (Roche) according to the manufacturer's protocol. The target sequence for TRPV3 specific siRNA (TRPV3-siRNA) was 5′-ACCUGCCUGAUGAAAGCUUTT-3′. A scrambled siRNA (TRPV3-sc)
sequence was considered as a negative control (5′-UUCUCCGAACGU-GUCACGUTT-3′). All sequences were synthesized by GenePharma Co.
Cells were divided into five groups: (1) control group; (2) model group:
cells were treated with 100 nmol L −1 Ang II for 48 hours; (3) siTRPV3 group: cells were pre-treated with TRPV3-siRNA transfection for 24 hours and finally exposed to 100 nmol L −1 Ang II for 48 hours; (4) N.C group: cells were transfected with TRPV3-sc for 24 hours followed by treatment with 100 nmol L −1 Ang II for 48 hours; (5) control+siTRPV3 group: cells were treated with TRPV3-siRNA transfection for 24 hours.
| Western blot
Protein samples were extracted from tissues and cells with the same procedures described previously. Briefly, the heart tissues and myocardial cells were lysed in RIPA buffer and then centrifuged at 4°C 
| Immunofluorescence staining
Immunofluorescence staining was performed to detect the expression of α-SMA in myocardial cells. In short, the cells were cultured on coverslips and received the desired treatment. At the end of the treatment, the cells were washed with PBS, fixed with 4% paraformaldehyde and permeabilized using 0.2% Triton X−100 . Cells were incubated with anti-α-SMA at 4°C overnight. Then, the second antibody was incubated in the dark. In the end, DAPI (Beyotime Biotechnology, Shanghai, China) was counterstained for the identification of nucleus. Photographs were acquired using fluorescence microscope (Leica, Heidelberg, Germany).
| Real-time polymerase chain reaction (RT-PCR)
Total 
| Tandem mRFP-GFP fluorescence microscopy
Cells transiently expressing mRFP-GFP-LC3 lentivirus were treated as designated and observed by laser microscopy. The number of GFP and mRFP puncta per cell were quantified manually.
| Statistical analysis
All data were expressed as mean ± SEM and analysed by using SPSS 19.0 software. Statistical analysis was performed with one-way ANOVA of variance. If the ANOVA was significant, SNK-q was used to evaluate the statistical significance of differences between two groups. P < 0.05 was considered to be a statistically significant difference.
| RESULTS

| Successfully established cardiac hypertrophy models in vivo and in vitro
To ensure the accuracy of the experiment, firstly we evaluated whether the cardiac hypertrophy models were successfully established Meanwhile, p62 expression was dramatically decreased ( Figure 2E and F). Above results suggested that autophagy was activated in hypertrophic hearts and cardiomyocytes.
| Effects of TRPV3 activation on cardiac hypertrophy
To better understand TRPV3-offered detrimental effects on cardiac hypertrophy, cardiac hypertrophy related mark proteins and cell surface areas were monitored. Firstly, we would confirm whether 
| Effects of TRPV3 activation on the activity of cardiac autophagy
To further explore the mechanism underneath by which TRPV3 aggravated cardiac hypertrophy, cardiac autophagy was detected.
As displayed in Figure 4 , autophagy related proteins Beclin-1 and LC3-II ( Figure 4A and B) were significantly increased, as well as p62 protein ( Figure 4C ) was decreased in model group, whereas silencing TRPV3 inhibited the expressions of Beclin-1 and LC3-II, and enhancing p62 expression. These data indicated that TRPV3 activation might promote cardiac autophagy, finally resulting in cardiac hypertrophy.
| Effects of miR-103 on cardiac hypertrophy
To determine the effect of miR-103 on cardiac hypertrophy, we used real-time PCR to measure the expression of miR-103 in rat myocardial tissues and neonatal cardiomyocytes. The results were shown in Figure 5A and B, and the expression of miR-103 in model group was lower than control group obviously in vivo and in vitro respectively. These results suggested that miR-103 might participate in cardiac hypertrophy regulation. To further investigate the effect of miR-103 on cardiac hypertrophy, we forced overexpression of miR-103 in neonatal rat ventricular myocytes (Figure 5C ). Overexpressing miR-103 dramatically inhibited cell surface area ( Figure 5D ) and the expressions of hypertrophy related mark proteins BNP ( Figure 5E ) and β-MHC ( Figure 5F ), as well as relative fluorescence intensity of Ca 2+ signal ( Figure 5G ), compared with model group. These data revealed that miR-103 had inhibitory effect on cardiac hypertrophy.
| Effects of miR-103 on the activity of cardiac autophagy
To further examine the potential mechanism of miR-103 overexpression protection against cardiac hypertrophy, cardiac autophagy was examined in cardiomyocytes. Autophagy is a dynamic process that involves autophagosome formation and lysosome degradation. To assess the effect of miR-103 on autophagic flux, the mRFP-GFP-LC3 assay was employed. In merged images, the yellow and red puncta These results implied that miR-103 suppressed cardiac hypertrophy partly via reducing the activity of cardiac autophagy.
| TRPV3 gene is a target of miR-103
Subsequently, we need to examine whether miR-103 directly targeted TRPV3. We used targetscan software to predict, and found a Interest in autophagy has increased in recent years as this highly conserved cellular process had been proved to implicate in a growing number of diseases including infection, cancer, neurodegeneration and ageing. 28 At the same time, it has also been reported that autophagy can promote the activation of inflammatory factors, 29 and plays a role in neurodegenerative diseases such as Parkinson's disease. 30 In recent years, studies have shown that autophagy is involved in the development of a variety of cardiovascular diseases. Huang reported that berberine alleviated cardiac ischaemia/reperfusion injury by inhibiting excessive autophagy in cardiomyocytes. 31 In addition, it has been reported that excessive cardiac autophagy can lead to cardiac hypertrophy. 32 Consistent with previous reports, our results indicated that excessive cardiac autophagy exacerbated cardiac hypertrophy in vivo and in vitro models.
The activation of TRPV3 channel is involved in the development of hyperphagia and obesity in obesity-prone rats by reducing food intake, 33 and also plays an important role in scars with post-burn pruritus by thymic stromal lymphopoietin (TSLP). 34 In addition to the above-mentioned effects, the TRPV3 channel is also involved in the regulation of cardiovascular diseases. Our previous studies have found that activation of TRPV3 channels can aggravate cardiac fibrosis in the pressure-overloaded rat hearts. 20 The present study further indicated that the expression of TRPV3 protein was significantly enhanced, both in vivo and in vitro of rat cardiac hypertrophy models. To further confirm the regulation of TRPV3 on cardiac hypertrophy, we used siRNA technology to silence TRPV3. After knockdown of TRPV3, the myocardial cell area was significantly reduced compared with the model group. At the same time, the expressions of cardiac hypertrophy marker proteins BNP and β-MHC, as well as intracellular calcium signal, were also significantly inhibited. Recently, accumulate evidence indicates that autophagy is activated in aortic banding model. 35, 36 Intriguingly, our results demonstrated that the expressions of Beclin-1 and LC3-II were also decreased, and p62 was increased, the important regulatory proteins 38 and overexpression of miR-27b could induce cardiac hypertrophy. 39 Wang reported that miR-103/ 107 could regulate programmed necrosis and myocardial ischaemia/ reperfusion injury through the FADD pathway. 40 However, whether miR-103 plays a role in cardiac hypertrophy has not been addressed.
The results of this experiment showed that miR-103 expression was decreased when cardiac hypertrophy occurred. This finding sug- 
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